{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T05:04:03Z","timestamp":1698728643060},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T00:00:00Z","timestamp":1242864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Background:<\/jats:bold> Androgen ablation is the standard treatment for advanced prostate cancer. However, most patients will eventually develop progressive hormone\u2010refractory prostate cancer (HRPC). The aim of the Pacl\u2010Vin study was to determine the efficacy and safety of paclitaxel in combination with vinorelbine in patients with HRPC, following from a phase I trial.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Thirty castrate patients with progressive, metastatic prostate cancer were enrolled. Patients were treated with paclitaxel 40\u2003mg\/m<jats:sup>2<\/jats:sup>, vinorelbine 20\u2003mg\/m<jats:sup>2<\/jats:sup> intravenously on day 1 and day 8 of a 21\u2010day cycle.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Two patients demonstrated a partial response and seven patients had stable disease from a cohort of 10 patients with measurable disease. Of 30 patients assessable for prostate\u2010specific antigen (PSA) response, 19 showed stable disease, which was maintained for at least 4\u2003weeks, while six (20%) experienced \u226550% decline in PSA levels. Median overall survival was 7.3\u2003months (interquartile range (IQR): 4.7\u20139.9\u2003months). Median progression\u2010free survival was 3.3\u2003months (IQR: 2.5\u20137.0\u2003months). Improvement in quality of life measures was noted after three cycles of therapy. Grade 3 and 4 toxicities were: neutropenia 8%, febrile neutropenia 4%, infection 2%, anaemia 3%, lethargy 1% and somnolescence 1%. One patient died as a result of neutropenic sepsis.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> In a poor prognostic cohort of patients paclitaxel and vinorelbine is a tolerable regimen, with a 20% PSA and objective response rate. The majority of patients achieved PSA stability. Furthermore, quality of life parameters, such as pain, were improved. However, the low level of activity of this regimen precludes its further testing.<\/jats:p>","DOI":"10.1111\/j.1445-5994.2009.01987.x","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T09:39:00Z","timestamp":1242898740000},"page":"201-208","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Phase II study of paclitaxel and vinorelbine (Pacl\u2010Vin) in hormone\u2010refractory metastatic prostate cancer: double tubulin targeting"],"prefix":"10.1111","volume":"40","author":[{"given":"S.","family":"Sewak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kosmider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Woollett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. G.","family":"Yeow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Le","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Debrincat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,15]]},"reference":[{"key":"e_1_2_7_2_2","unstructured":"GilesG ThursfieldV.Canstat Cancer Epidemiology Centre The Cancer Council Victoria. [cited 2004]. Available from URL:http:\/\/www.cancervic.org.au"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1998.tb141478.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041318"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040720"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.100"},{"issue":"2","key":"e_1_2_7_7_2","first-page":"5","article-title":"In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence","volume":"16","author":"Binet S","year":"1989","journal-title":"Semin Oncol"},{"key":"e_1_2_7_8_2","unstructured":"VaughnD BrownA HarkerW HuhS MillerG RinaldiDet\u2003al.Phase II evaluation of weekly paclitaxel and estramustine phosphate in androgen\u2010independent prostate cancer.ASCO Annual Meeting2003;22:402(Abstract 1615)."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199448050-00009"},{"key":"e_1_2_7_10_2","first-page":"586","article-title":"Synergy analysis of vinorelbine and paclitaxel in prostate cancer","volume":"39","author":"De Souza P","year":"1998","journal-title":"Proc Am Ass Cancer Res"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20000715)89:2<431::AID-CNCR31>3.0.CO;2-B"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh429"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200301000-00009"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.3109\/07357909009012056"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70284-X"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00025-6"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.3.205"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3461"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-004-0980-1"},{"issue":"20","key":"e_1_2_7_21_2","doi-asserted-by":"crossref","first-page":"6094","DOI":"10.1158\/1078-0432.CCR-06-1188","article-title":"Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone\u2010refractory prostate cancer with pharmacogenetic survival analysis","volume":"12","author":"Hahn NM","year":"2006","journal-title":"Clin Cancer Res"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2007.02.060"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1445-5994.2009.01987.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1445-5994.2009.01987.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:38:44Z","timestamp":1698658724000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1445-5994.2009.01987.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1111\/j.1445-5994.2009.01987.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1445-5994.2009.01987.x","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"2010-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}